Publicity. Neither Party will use the name of the other Party or the other Party’s employees or any of their trademarks in any advertising, sales promotional material, or press release without the other Party’s prior written approval, except to the extent such disclosure is reasonably necessary for:
Publicity. Customer is permitted to state publicly that it is a customer of the Services, consistent with the Trademark Guidelines. If Customer wishes to display Google Brand Features or Revolgy Brand Features in connection with its use of the Services, Customer must obtain written permission from Google or Revolgy through the process specified in the Trademark Guidelines in relation to Google or by contacting Revolgy’s representative in case of Revolgy. Google and Revolgy may include Customer’s name or Brand Features in a list of Google customers or Revolgy customers, online or in promotional materials. Google and Revolgy may also verbally reference Customer as a customer of the Services. Neither party needs approval for repeating a public statement that is substantially similar to a previously approved public statement. Any use of a party’s Brand Features will inure to the benefit of the party holding Intellectual Property Rights to those Brand Features. A party may revoke the other party’s right to use its Brand Features under this Clause by giving written notice to the other party and allowing a reasonable period to stop the use.
Publicity. Neither party shall use the name of the other party in any publicity, advertising or announcement without the other party’s prior written approval. The foregoing restriction shall also apply to Provider of Medical Services’ and Principal Investigator’s use of the name and/or trademark of any third parties collaborating with AbbVie on the Study (“AbbVie Collaborators”). In accordance with the foregoing, Provider of Medical Services agrees, subject to the terms of Section 6 of the Agreement, to publish this Agreement in the Registry of Agreements at xxxxxxx.xxx.xx in accordance with the terms of 340/2015 Coll. Act on Register of Contracts (the “Act”) within two (2) business days of full execution of the Agreement and to promptly notify AbbVie of publication. Should Provider of Medical Services fail to publish this Agreement within thirty (30) days of fully execution of the Agreement, AbbVie reserves the right to publish this Agreement as required under the Act. AbbVie and Provider of Medical Services hereby agree that: (i) Exhibit C attached hereto represents: (i) a redacted version of the Agreement, amended in accordance with the Act by removing all sections and exhibits which include confidential information, personal details and trade secrets; and (ii) the redacted Agreement attached hereto as Exhibit C shall be the version of the Agreement to be published in accordance with the Act. For purposes of clarity, exhibits such as the Budget, the Protocol, insurance certificates and information regarding patient reimbursement shall not be included in the redacted version of the Agreement to be published in accordance with the Act.
Publicity. Neither party shall use the name of the other party in any publicity, advertising or announcement without the other party’s prior written approval. In accordance with the foregoing, Provider of Medical Services agrees, subject to the terms of Section 7 of the Agreement, to publish this Agreement in the Registry of Agreements at xxxxxxx.xxx.xx in accordance with the terms of 340/2015 Coll. Act on Register of Contracts (the “Act”) within five (5) business days of full execution of the Agreement and to promptly notify AbbVie of publication. Should Provider of Medical Services fail to publish this Agreement within thirty (30) days of fully execution of the Agreement, AbbVie reserves the right to publish this Agreement as required under the Act. AbbVie and Provider of Medical Services hereby agree that: (i) Exhibit D attached hereto represents: (i) a redacted version of the Agreement, amended in accordance with the Act by removing all sections and exhibits which include confidential information, personal details and trade secrets; and (ii) the redacted Agreement attached hereto as Exhibit D shall be the version of the Agreement to be published in accordance with the Act. For purposes of clarity, exhibits such as the Budget, the Protocol, insurance certificates and information regarding subject reimbursement shall not be included in the redacted version of the Agreement to be published in accordance with the Act.
Publicity. Neither party shall use the name of the other party in any publicity, advertising or announcement without the other party’s prior written approval. In accordance with the foregoing, Provider of Medical Services agrees to publish this Agreement in the Registry of Agreements at xxxxxxx.xxx.xx in accordance with the terms of 340/2015 Coll., Act on Register of Contracts, as amended (the “Act”) within ten
Publicity. Except as required by law, Institution shall not and shall ensure Receiving Party shall not disclose the existence or terms of this Agreement or use the name, trademark, servicemark or logo of CRO or Sponsor in any publicity, advertising or information, which is disseminated to any third person or to the general public without CRO’s or Sponsor’s prior written approval. Institution understands that the terms and conditions of this Agreement, including the amount of any payment made hereunder, may be disclosed and made public by CRO or Sponsor as required by law or regulation or where Sponsor deems appropriate.
Publicity. Without a prior written consent of the Buyer the Supplier may not advertise or publish any goods or services supplied or rendered by the Supplier to the Buyer (articles, photographs, films, advertising banners or websites, etc.). In the event this obligation is not adhered to, the Buyer reserves the right to remove any advertisements or publications at the expense of the Supplier.
Publicity. Neither party shall use the name of the other party in any publicity, advertising or announcement without the other party’s prior written approval. In accordance with the foregoing, Institution agrees, subject to the terms of this Agreement, to publish Redacted version of this Agreement in the Registry of Agreements at xxxxxxx.xxx.xx in accordance with the terms of 340/2015 Coll. Act on Register
Publicity. Except as required under Act. No. 106/1999 on free access to information, PHARMACY shall not disclose the existence or terms of this Agreement or use CRO's or Sponsor's name, trademark, servicemark or logo in any publicity, advertising, Legal Template: Czech Republic-Clinical Study Agreement (Pharmacy) (Bilingual) 22APR2014 Document Name:[Xx xX] _CZE_ AbbVie M13-538 Pharmacy Agreement_clean_12Nov2014 .doc Page 8 of 20 publicitě, reklamě nebo informacích, které se poskytují jakékoliv třetí osobě nebo veřejnosti, bez předchozího písemného schválení CRO nebo Zadavatele. V případě potřeby zveřejnění podmínek této smlouvy dle výše uvedeného zákona, ZZ - lékárna souhlasí s tím, že bude v dobré víře spolupracovat se Zadavatelem a CRO, a že mu poskytne přesné informace v souvislosti s touto žádostí o zveřejnění. ZZ - lékárna bere na vědomí, že podmínky této Smlouvy, včetně částky jakékol iv platby provedené na základě této Smlouvy, mohou být poskytnuty a zveřejněny CRO nebo Zadavatelem, jak vyžaduje zákon nebo nařízení nebo tam, kde to Zadavatel považuje za vhodné.
Publicity. Neither Party will use the name of the other Party or the other Party’s employees or any of their trademarks in any advertising, sales promotional material, or press release without the other Party’s prior written approval, except to the extent such disclosure is reasonably necessary for: (i) regulatory filings, including filings with the U.S. Securities and Exchange Commission or the FDA (or any equivalent oversight body in a country other than the United States); (ii) prosecuting or defending litigation; and (iii) complying with applicable laws, rules, and regulations. Notwithstanding the foregoing, Sponsor may, without prior consent, publicly disclose information about Provider and Investigator as required by applicable law, including, but not limited to identifying Provider as the entity that is conducting the Trial, Investigator as conducting the Trial at Provider, and the amount of funding provided to Provider by Sponsor for the conduct of the Trial. Provider and Investigator consent to this disclosure. Provider and Investigator may, without prior consent, disclose in Provider’s confidential internal reports or governmental reports and grant applications, their participation in the Trial (including Sponsor’s name, the name of the Trial and Protocol number).